Advanced search
Publication Cover
The Aging Male Volume 26, 2023 - Issue 1
Submit an article Journal homepage
2,824
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Risk analysis of metformin use in prostate cancer: a national population-based study

Jung Ki Joa Department of Urology, College of Medicine, Hanyang University, Seoul, Korea;b Department of Medical and Digital Engineering, Hanyang University, Seoul, KoreaCorrespondence[email protected]
View further author information
,
Hae Kyung Songb Department of Medical and Digital Engineering, Hanyang University, Seoul, KoreaView further author information
,
YongKi Heob Department of Medical and Digital Engineering, Hanyang University, Seoul, KoreaView further author information
,
Mi Jeong Kimb Department of Medical and Digital Engineering, Hanyang University, Seoul, KoreaView further author information
&
Yun Jin Kimc Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, KoreaView further author information
Article: 2156497 | Received 27 May 2022, Accepted 04 Dec 2022, Published online: 28 Mar 2023

References

  • Ries L, Melbert D, Krapcho M, et al. 2008. SEER cancer statistics review, 1975–2005, based on November 2007 SEER data submission, posted to the SEER website. Available from: http://seer.cancer.gov/csr/1975_2005/.
  • Hsing AW, Gao YT, Chua S, Jr, et al. Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003;95(1):67–71.
  • Giovannucci E. Metabolic syndrome, hyperinsulinemia, and Colon cancer: a review. Am J Clin Nutr. 2007;86(3):836S–842S.
  • Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1977–1983.
  • Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. J Clin Oncol. 2004;22(3):446–453.
  • Venkateswaran V, Haddad AQ, Fleshner NE, et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007;99(23):1793–1800.
  • Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071–1078.
  • Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow‐up study. Int J Cancer. 2009;124(6):1398–1403.
  • U.S. Food and Drug Administration. Metformin Hydrochloride Tablets [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2016. [updated Apr 29, 2016; cited 2016 Mar 1]. Available from: www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf.
  • Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 1998;6(2):89–131.
  • Akinyeke T, Matsumura S, Wang X, et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013;34(12):2823–2832.
  • Lee J, Lee JS, Park S-H, et al. Cohort profile: the national health insurance service-national sample cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017; 46(2):e15.
  • Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745–6752.
  • Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–1305.
  • Murtola TJ, Tammela TL, Lahtela J, et al. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol. 2008;168(8):925–931.
  • Waters KM, Henderson BE, Stram DO, et al. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 2009;169(8):937–945.
  • Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9):1898–1906.
  • Burcelin R. The antidiabetic gutsy role of metformin uncovered? Gut. 2014;63(5):706–707.
  • Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–546.
  • Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70(6):2465–2475.
  • Kim CH, Han KA, Oh HJ, et al. Safety, tolerability, and efficacy of metformin extended‐release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia. J Diabetes. 2012;4(4):395–406.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.